At one year (primary analysis), 91.3 % (p=0.005) of patients receiving Bonviva 150 mg once monthly had a lumbar spine BMD increase above or equal to baseline (BMD responders), compared with 84.0 % of patients receiving ibandronic acid 2.5 mg daily.
Po enem letu (primarna analiza) se je 91, 3 % (p = 0, 005) bolnikom, ki so prejemali Bonvivo 150 mg enkrat na mesec, MKG lumbalne hrbtenice povišala ali ostala enaka izhodiščni vrednosti (bolniki, odzivni na povišanje MKG) v primerjavi s 84, 0 % bolnikov, ki so prejemali ibandronsko kislino 2, 5 mg na dan.